by Leigh Purvis, Public Policy Institute, May 1, 2009
Spending on biologic drugs is growing nearly twice as quickly as spending on traditionally developed “small molecule” drugs. One factor in the increase in spending on biologics is the lack of a statutory pathway to approve generic, or bio-equivalent, biologic drugs.
Biologics are quickly becoming a common treatment option. Many of the new indications are for conditions that primarily affect older populations, such as cancer, rheumatoid arthritis, and multiple sclerosis. However, given the substantial out-of-pocket costs that can be associated with using biologic drugs, many patients will face impeded access until generic biologic drugs become available
Please leave your comment below.
You must be logged in to leave a comment.
Members save on in-home caregiving services.
Members get 10% off monthly fees, plus free installation and package savings on a safety monitoring system.
Members can take a free confidential hearing test by phone.
AARP members receive exclusive member benefits & affect social change.
You are leaving AARP.org and going to the website of our trusted provider. The provider’s terms, conditions and policies apply. Please return to AARP.org to learn more about other benefits.
Your email address is now confirmed.
Manage your email preferences and tell us which topics interest you so that we can prioritize the information you receive.
Explore all that AARP has to offer.
In the next 24 hours, you will receive an email to confirm your subscription to receive emails
related to AARP volunteering. Once you confirm that subscription, you will regularly
receive communications related to AARP volunteering. In the meantime, please feel free
to search for ways to make a difference in your community at